Drug intelligence / Profile preview

naproxen + pregabalin

Development stage
Preclinical
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

Naproxen + pregabalin is a combination therapy consisting of two distinct pharmaceutical agents used primarily for the management of pain, particularly neuropathic and inflammatory pain. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) enzymes, leading to decreased prostaglandin synthesis and thus reducing inflammation, pain, and fever[5]. Pregabalin is an anticonvulsant and analgesic agent that binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, modulating neurotransmitter release involved in pain signaling[3][6]. Preclinical studies suggest that this combination can act synergistically or additively to reverse hyperalgesia in models of inflammatory or neuropathic pain[4][8]. The combination may be considered when monotherapy with either agent does not provide sufficient relief.

02

Targets

α2δ (Voltage-gated calcium channel alpha-2-delta subunit)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on naproxen + pregabalin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on naproxen + pregabalin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call